New combo aims to stall advanced lung cancer
NCT ID NCT05798663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding the immunotherapy drugs atezolizumab (with or without tiragolumab) to standard chemoradiotherapy can help people with stage III lung cancer that cannot be removed by surgery. About 178 participants will receive the drugs before, during, and after radiation and chemotherapy. The main goal is to see if the combination delays cancer progression or improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) and tiragolumab, given with chemotherapy and radiation
What this could lead to
If successful, this could point toward a more effective treatment regimen for advanced lung cancer that delays disease progression.
What could go wrong
This is an early-phase trial with only 178 participants, so results may not apply to all patients. Adding immunotherapy also carries risks of immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Oncology Associates of Central New York, P.C.
East Syracuse, New York, 13057, United States
-
Kaiser Permanente Oakland Medical Center
Oakland, California, 94611, United States
-
Kaiser Permanente Roseville Medical Center
Roseville, California, 95661, United States
-
Kaiser Permanente San Francisco Medical Center
San Francisco, California, 94115, United States
-
Kaiser Permanente Santa Clara Medical Center
Santa Clara, California, 95051, United States
-
Kaiser Permanente Vallejo Medical Center
Vallejo, California, 94589, United States
-
Missouri Baptist Medical Center
St Louis, Missouri, 63131, United States
-
New Hampshire Oncology - Hematology, PA
Manchester, New Hampshire, 03103, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
University of California San Diego Moores Cancer Center
La Jolla, California, 92037, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63110, United States